Akari Therapeutics to Present Trop2 ADC Poster at AACR Meeting on April 20
Akari Therapeutics’ abstract on its Trop2-targeting ADC (poster 3179) for bladder, lung and breast tumors will be presented April 20, 2026 at the AACR Annual Meeting. The company has initiated IND-enabling studies for lead candidate AKTX-101 and plans a First-In-Human trial in late 2026/early 2027.
1. Poster Presentation Accepted
Akari Therapeutics has had its abstract titled “Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast” accepted for poster presentation (Poster 3179, Board 14) at the AACR Annual Meeting on April 20, 2026. The session on Experimental and Molecular Therapeutics will feature this poster between 2:00 PM and 5:00 PM PT in Poster Section 19.
2. Lead Candidate IND-Enabling
The company has initiated IND-enabling studies for its lead antibody drug conjugate, AKTX-101, which uses the novel PH1 spliceosome-modulating payload to target the Trop2 receptor. Akari aims to start a First-In-Human trial of AKTX-101 in late 2026 or early 2027, leveraging preclinical data showing significant antitumor activity and immune activation.
3. Pipeline Expansion
In addition to AKTX-101, Akari is developing AKTX-102, an ADC targeting CEACAM5 across multiple solid tumors. AKTX-102 employs the same PH1 payload and a proprietary antibody construct designed to enhance tumor cell killing and immune response.